Ibrahim Osman, MD
Cardiovascular Disease · Roseburg, ORNPI 1417225939
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Medtronic at 43.0% of the total. Among cardiovascular disease clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 246 payments — averaging $77.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Penumbra, Inc.$4K
- Abbott$2K
- Boston Scientific$1K
- Abiomed$462
- Johnson & Johnson$360
- plus $3K from 28 others
What the payments were for
- Travel & lodging$10,44355%
- Food & beverage$8,55645%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 75 | $8,183 |
| Penumbra, Inc. | 8 | $3,861 |
| Abbott | 15 | $1,944 |
| Boston Scientific | 10 | $1,159 |
| Abiomed | 12 | $462 |
| Johnson & Johnson | 16 | $360 |
| Inari Medical, Inc. | 3 | $314 |
| Novartis | 24 | $300 |
| Bayer | 2 | $250 |
| Edwards Lifesciences | 2 | $243 |
| AstraZeneca | 15 | $213 |
| Asahi Intecc USA, Inc. | 1 | $180 |
| Cardiovascular Systems Inc. | 3 | $168 |
| Terumo Medical Corporation | 3 | $163 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $149 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $135 |
| Boehringer Ingelheim | 8 | $126 |
| Regeneron Healthcare Solutions, Inc. | 10 | $109 |
| Chiesi USA, Inc. | 1 | $108 |
| E.r. Squibb & Sons, L.L.C. | 6 | $81 |
| Kowa Pharmaceuticals America, Inc. | 4 | $78 |
| Acist Medical Systems, Inc. | 1 | $67 |
| Amgen | 5 | $67 |
| Pfizer | 4 | $65 |
| Bridgebio Pharma, Inc. | 1 | $64 |
| ZOLL Circulation Inc | 1 | $48 |
| Biotronik Inc. | 1 | $22 |
| Philips North America LLC | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Merck | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$3,787
- MitraClip$1,602
- Micra$1,119
- Attain$1,081
- SQ RX PULSE GENERATOR$717
- Advisa$645
- FLOWTRIEVER CATHETER, S$456
- Kerendia$250
- SAPIEN 3 Ultra RESILIA$212
- PRESSUREWIRE$189
- ASAHI PTCA Guide Wire$180
- AURORA EV-ICD MRI SURESCAN$170
- XARELTO$125
- Diamondback Coronary$124
- KENGREAL$108
- ATTAIN COMMAND + SUREVALVE$104
- GLIDESHEATH SLENDER$100
How this compares
$19,032 in reported general payments places this provider in the 90th percentile of 198 cardiovascular disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 87 | $105,657 |
| XareltoRivaroxaban | 49 | $60,838 |
| Repatha SureclickEvolocumab | 20 | $16,020 |
| Metoprolol Succinate | 134 | $2,161 |
| Atorvastatin Calcium | 49 | $1,147 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 35 | $974 |
| Flecainide Acetate | 13 | $593 |
| ClopidogrelClopidogrel Bisulfate | 35 | $451 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $438 |
| Amiodarone Hcl | 17 | $436 |
| Carvedilol | 23 | $373 |
| Amlodipine Besylate | 37 | $340 |
| Digoxin | 11 | $301 |
| Torsemide | 19 | $255 |
| Potassium Chloride | 11 | $226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $65 | $105,65787 claims |
| Johnson & JohnsonXarelto | $360 | $60,83849 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 198 cardiovascular disease providers in Oregon.
Other cardiovascular disease in Roseburg
- Gary BronsteinRoseburg$3K
- Firas ZahrPortland$810K
- Kathy GreweHood River$376K
- Scott ChadderdonPortland$282K
- Ahmad MasriPortland$227K
- Ashwat DhillonCorvallis$156K
- Stephen HeitnerPortland$105K
- Ian RiddockBend$81K
- Abhushan PoudyalPortland$54K
- Douglas DawleyPortland$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.